Amylyx Pharmaceuticals, Inc. (AMLX) Operating cash flow 2021–2025
Amylyx Pharmaceuticals, Inc. (AMLX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$123.3MFY2025 · since FY2021: -$74.8M → -$123.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$123.3M | +26.4% |
| FY2024 | -$167.6M | -1506.6% |
| FY2023 | $11.9M | +106.6% |
| FY2022 | -$179.9M | -140.5% |
| FY2021 | -$74.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AMLX financial trends
AMLX RevenueAMLX Net incomeAMLX Net marginAMLX Gross profitAMLX Gross marginAMLX Operating incomeAMLX Operating marginAMLX Free cash flowAMLX Capital expendituresAMLX Return on equityAMLX Stock buybacksAMLX Dividends paidAMLX Total assetsAMLX Total liabilitiesAMLX Shareholders’ equityAMLX overview →